Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib ...
Results from the POETYK PSO-1 and POETYK PSO-2 showed that 58% and 53% respectively of patients treated with Sotyktu achieved 75% skin clearance, versus 35% and 40% for Otezla. BMS has set a list ...
We’re a most expensive city. Taxed city. Crowded city. Dirty city. Scary subway. Housing costs. Overcrowding, crime, creative politicians. And that’s our good stuff.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback